Added to YB: 2026-07-10
Pitch date: 2026-07-08
ERAS [bullish]
Erasca, Inc.
+1.16%
current return
Author Info
No bio for this author
Company Info
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Market Cap
$5.7B
Pitch Price
$18.96
Price Target
30.00 (+59%)
Dividend
N/A
EV/EBITDA
-43.64
P/E
-19.14
EV/Sales
N/A
Sector
Biotechnology
Category
growth
New Long Idea - Erasca, Inc.
ERAS: RAS(ON)/pan-RAS niche MRK got priced out of on RVMD; ~$7B FD MC, ~$400M cash, PT $30. Better CypA affinity→wider therapeutic index, cleaner safety. Wins on combo/earlier-line vs RVMD at 1/4 cost. M&A thesis: MRK (live clinical tie) & ABBV likely bidders. Catalysts: ERAS4001 ph1 H2'26, mono+combo data H1'27.
Read full article (2 min)